How to Get Vyleesi (Bremelanotide) in Vermont

What Is Vyleesi and Who Is It For?

Bremelanotide, sold under the brand name Vyleesi, is an on-demand subcutaneous injection approved by the FDA in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not indicated for postmenopausal women or for men. The drug works by activating melanocortin-4 receptors (MC4R) in the central nervous system, a mechanism distinct from flibanserin's serotonergic pathway.

How Bremelanotide Differs From Flibanserin

Flibanserin (Addyi) requires daily oral dosing and carries an alcohol interaction boxed warning. Bremelanotide is used only when needed, carries no alcohol restriction, and acts through a completely separate receptor system. The RECONNECT trial (N=1,247) demonstrated that bremelanotide 1.75 mg produced a statistically significant increase in desire score (+0.57 on the FSFI desire domain vs. +0.21 for placebo, P<0.001) and a significant reduction in distress as measured by the FSDS-DAO [1].

FDA-Approved Dosing

Patients self-administer 1.75 mg subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. The FDA label caps use at one dose per 24-hour period and no more than 8 doses per calendar month [2]. Nausea is the most common adverse event, reported in roughly 40% of patients in clinical trials, though it tends to diminish with repeated use.

Step-by-Step: Getting a Vyleesi Prescription in Vermont

The process from initial consultation to first injection typically takes 7 to 21 days in Vermont, depending on insurance type and pharmacy routing. Here is the full workflow.

Step 1: Schedule a Clinical Evaluation

Any Vermont-licensed MD, DO, NP (APRN), or PA with prescriptive authority can diagnose HSDD and prescribe bremelanotide. You do not need a specialist referral. A primary care provider, OB-GYN, or sexual medicine clinician can handle the evaluation. The visit should include a thorough sexual health history, assessment of relationship and psychological factors, medication review (SSRIs and hormonal contraceptives can contribute to low desire), and screening for other causes of reduced libido such as thyroid dysfunction or depression.

Step 2: Complete Baseline Labs

No specific lab panel is FDA-mandated before starting Vyleesi. Clinicians in Vermont typically order a baseline blood pressure reading (bremelanotide can cause transient hypertension) and may check thyroid function (TSH), prolactin, and a metabolic panel to rule out organic causes of low desire. The Endocrine Society's 2019 guideline on female sexual dysfunction recommends ruling out hormonal and medical etiologies before diagnosing HSDD [3].

Step 3: Receive the Prescription

Once HSDD is confirmed and the prescriber determines bremelanotide is appropriate, the prescription is sent electronically to a pharmacy. Vermont law permits e-prescribing for non-controlled substances, and bremelanotide is not a scheduled drug.

Telehealth Access to Vyleesi in Vermont

Vermont permits full prescriptive authority via telehealth for non-controlled medications. This means a patient in Burlington, Montpelier, or any rural Vermont town can receive a bremelanotide prescription through a synchronous video visit without ever entering a brick-and-mortar clinic.

Vermont Telehealth Regulations

Under Vermont's telehealth parity law (Act 25, 2015), insurers must cover telehealth visits at the same rate as in-person visits. The provider must hold a Vermont medical license or be authorized under an interstate compact. Audio-only visits may qualify for select payers, but a video component is standard practice for initial HSDD evaluations, since the clinician needs to discuss sensitive topics and observe patient engagement.

Choosing a Telehealth Provider

Several national telehealth platforms now include HSDD consultations in their service lines. When selecting a provider, verify three things: that the clinician holds an active Vermont license, that the platform can submit prior authorization paperwork on your behalf, and that they send prescriptions to pharmacies that stock or can order Vyleesi autoinjectors.

Insurance Coverage and Prior Authorization in Vermont

Coverage for Vyleesi varies sharply by payer. The branded autoinjector carries a wholesale acquisition cost near $950 per dose, making insurance or manufacturer assistance programs a practical necessity for most patients.

Vermont Medicaid

Vermont Medicaid (Green Mountain Care) covers bremelanotide with prior authorization. The PA process requires the prescriber to document a confirmed HSDD diagnosis (using DSM-5 criteria), evidence that the condition is acquired and generalized (not situational), confirmation that the patient is premenopausal, and notation that contributing medical causes have been evaluated and addressed.

Private Insurance

Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna plans sold on the Vermont exchange each maintain their own formulary placement for Vyleesi. Most commercial plans classify bremelanotide as a specialty-tier drug requiring prior authorization. According to IQVIA data published through the National Institutes of Health, specialty-tier medications face PA approval rates between 60% and 80% on first submission [4]. A peer-to-peer review between your prescriber and the plan's medical director can often overturn an initial denial.

Documentation for Prior Authorization

A typical PA submission in Vermont requires:

• A signed letter of medical necessity from the prescribing clinician
• DSM-5-based HSDD diagnosis with documentation of symptom duration (generally 6+ months)
• Record that organic causes (hypothyroidism, hyperprolactinemia, medication side effects) have been excluded
• Statement confirming the patient is premenopausal
• Prior treatment history, if any (some plans require a trial of counseling or flibanserin before approving bremelanotide)

Expect a PA turnaround of 5 to 15 business days. Vermont insurance regulations require payers to respond to non-urgent PA requests within two business days for commercial plans under state prompt-response rules, though specialty drug requests sometimes take longer in practice.

Manufacturer Savings Programs

Palatin Technologies partners with a patient support hub that offers copay cards for commercially insured patients. Eligible patients may pay as little as $0 per dose for up to 12 months, subject to annual caps. Uninsured patients should ask about the patient assistance program directly through the Vyleesi website or the prescribing clinician's office.

Pharmacy Options in Vermont

Not every retail pharmacy in Vermont stocks Vyleesi autoinjectors. The drug's cold-chain requirements and relatively low prescription volume mean most patients fill through one of three channels.

Retail and Specialty Pharmacies

Large chains (CVS, Walgreens, Rite Aid) can order Vyleesi, but turnaround is typically 3 to 5 business days after the prescription arrives. Specialty pharmacies affiliated with insurance plans (such as CVS Specialty or Accredo) often provide faster fulfillment and handle PA paperwork directly. Specialty pharmacies also offer injection training by phone, which is especially valuable for patients unfamiliar with subcutaneous self-injection.

503A Compounding Pharmacies

Vermont-licensed 503A compounding pharmacies can prepare bremelanotide for individual patients with a valid prescription. Compounded bremelanotide may cost less than the branded autoinjector, though pricing varies by pharmacy. The FDA's guidance on 503A compounding permits these pharmacies to compound drugs that are commercially available only when the prescriber documents a clinical need for a customized formulation (for example, a different concentration or preservative-free preparation) [5]. Patients should confirm the 503A pharmacy holds a current Vermont Board of Pharmacy license and ships under appropriate cold-chain protocols.

Mail-Order Delivery Timelines

Most Vermont patients receive Vyleesi within 5 to 10 business days after PA approval when using mail-order specialty pharmacies. Rural Vermont addresses (the Northeast Kingdom, for instance) may add 1 to 2 business days for delivery. Autoinjectors ship in insulated packaging with cold packs to maintain stability.

Who Can Prescribe Vyleesi in Vermont

Vermont's scope-of-practice laws give full prescriptive authority to multiple provider types.

Physicians (MD/DO)

Any physician with an active Vermont medical license can prescribe bremelanotide. OB-GYNs and sexual medicine specialists are the most common prescribers, but internists and family medicine physicians prescribe it as well.

Nurse Practitioners (APRNs)

Vermont grants APRNs full practice authority under 26 V.S.A. § 1613. An APRN with prescriptive authority does not need a collaborative agreement with a physician to prescribe Vyleesi. This is particularly relevant in rural Vermont, where NPs often serve as the primary provider.

Physician Assistants (PAs)

PAs in Vermont prescribe under a delegatory agreement with a supervising physician. A PA can prescribe bremelanotide as long as the supervising physician's practice scope includes this drug category and the delegation agreement does not exclude it.

Clinical Considerations Before Starting Vyleesi

Bremelanotide is not appropriate for every patient with low desire. Several clinical factors require evaluation before the first dose.

Cardiovascular Screening

The RECONNECT trial showed bremelanotide causes a transient increase in systolic blood pressure of approximately 6 mmHg and a decrease in heart rate of roughly 5 bpm within the first few hours after injection [1]. The FDA label contraindicates Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease [2]. A baseline blood pressure check is the minimum cardiovascular screen. Patients with a resting systolic pressure above 140 mmHg should achieve adequate blood pressure control before starting the drug.

Nausea Management

Roughly 40% of patients in the RECONNECT trial experienced nausea, and about 13% experienced it severely enough to consider discontinuation [1]. Nausea typically peaks with the first few doses and attenuates over time. Some clinicians recommend taking an antiemetic (ondansetron 4 mg) 30 minutes before the first one or two injections to ease the transition. Eating a light meal 1 to 2 hours before injection may also reduce symptoms.

Drug Interactions

Bremelanotide slows gastric emptying transiently. The FDA label warns against using it concurrently with oral naltrexone, as bremelanotide may reduce naltrexone absorption. Patients using oral medications with narrow therapeutic windows should discuss timing adjustments with their prescriber. There are no known interactions with hormonal contraceptives, SSRIs, or common antihypertensives based on current pharmacokinetic data from the prescribing information [2].

Skin Hyperpigmentation

Approximately 1% of patients in clinical trials developed focal skin hyperpigmentation, most commonly on the face and gums. The hyperpigmentation resolved slowly after discontinuation in most cases but persisted in some. Patients with darker skin tones should be counseled about this risk and monitored at follow-up.

What to Expect After Your First Dose

Onset of effect is approximately 45 to 60 minutes post-injection. The RECONNECT trial data showed that bremelanotide's effect on desire was measurable within the first month of as-needed use, with continued benefit through 24 weeks of the study [1]. Not every patient responds. In the trial, the placebo-subtracted improvement in desire score was modest (approximately 0.36 points on the FSFI desire domain), and about 25% of bremelanotide-treated patients did not report meaningful improvement. The FDA label recommends discontinuing Vyleesi if no benefit is perceived after 8 weeks of use.

Patients should schedule a follow-up visit (in person or via telehealth) 4 to 8 weeks after starting treatment to assess efficacy, tolerability, and whether dose-timing adjustments improve the experience. Blood pressure should be rechecked at this visit.

Transferring a Vyleesi Prescription to Vermont

If you hold an active Vyleesi prescription from another state, a Vermont-licensed pharmacy can accept a transferred prescription under standard interstate transfer rules. The originating pharmacy calls the receiving Vermont pharmacy to transfer the prescription record. Controlled-substance transfer restrictions do not apply because bremelanotide is unscheduled. If your out-of-state prescriber is not licensed in Vermont, a Vermont-licensed provider must write a new prescription after a consultation (telehealth is sufficient).